Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Research Toward a Cure Trials

A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry.

Published
02 October 2014
From
Treatment Action Group
Why I Refused, Then Later Embraced, HIV Treatment

"On good days, adhering to my pill is a positive affirmation of my life, an exercise in self-love. On bad days, it's just a pill I need to swallow, not terribly bitter but as mildly annoying as having to shave or tie my shoelaces every day. It's yet another thing to add to my list of things, but I do it anyway." Josh Kruger on his ambiguous relationship to HIV treatment.

Published
01 October 2014
From
TheBody.com
Monkey Study Suggests Radiation Didn’t Cure ‘Berlin Patient’ of HIV

A primate study has suggested that the radiation part of the leukemia treatment the “Berlin patient” received was not what functionally cured him of HIV.

Published
01 October 2014
From
AIDSMeds
Exclusive: India set to run out of critical free drug for HIV/AIDS program

India could run out of a critical medicine in its free HIV/AIDS drugs program in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month.

Published
01 October 2014
From
Reuters
CHMP Announces Positive Opinion for REZOLSTA™, a New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir and Cobicistat

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a Positive Opinion recommending REZOLSTA™ (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. The CHMP also announced two label extensions for darunavir, a protease inhibitor marketed as PREZISTA® by Janssen.

Published
01 October 2014
From
Janssen press release
Polypharmacy Hinders HIV Drug Adherence

Among HIV-positive patients, concurrent use of medications is associated with nonadherence to antiretroviral therapy (ART), according to research published in the Journal of Managed Care & Specialty Pharmacy.

Published
29 September 2014
From
Pharmacy Times
How did the 'Berlin patient' rid himself of HIV?

Researchers are closer to unraveling the mystery of how Timothy Ray Brown, the only human cured of HIV, defeated the virus, according to a new study. Although the work doesn’t provide a definitive answer, it rules out one possible explanation.

Published
29 September 2014
From
Science
Doctor treats Ebola with HIV drug in Liberia - seemingly successfully

A doctor in rural Liberia inundated with Ebola patients says he's had good results with a treatment he tried out of sheer desperation: an HIV drug. Dr. Gobee Logan has given the drug, lamivudine, to 15 Ebola patients, and all but two survived. That's a 7% mortality rate whereas across West Africa, the virus has killed 70% of its victims.

Published
27 September 2014
From
CNN
Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved by FDA as Individual HIV Drugs

A next-generation boosting agent and an integrase inhibitor joined the growing ranks of approved HIV medications on Sept. 24, when the U.S. Food and Drug Administration (FDA) stamped its seal of approval on Tybost (known generically as cobicistat) and Vitekta (elvitegravir).

Published
26 September 2014
From
The Body
Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

The studies demonstrated that the single tablet regimen comprising elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF), was non-inferior to Gilead’s Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL at 48 weeks of therapy. In addition, E/C/F/TAF demonstrated more favorable renal and bone safety compared to Stribild.

Published
25 September 2014
From
Gilead press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.